You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Plasmablastic Lymphom

Showing 1 - 25 of 5,438
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Recruiting
  • Relapsed Plasmablastic Lymphoma
  • +2 more
  • Belantamab Mafodotin
  • Boston, Massachusetts
  • +2 more
Sep 20, 2021

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

Recruiting
  • Epstein-Barr Virus Associated Lymphoproliferative Disorder
  • +7 more
  • Nanatinostat in combination with valganciclovir
  • Birmingham, Alabama
  • +57 more
Aug 10, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
Mar 24, 2022

Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin Trial in United States (Autologous transplantation

Completed
Has Results
  • Lymphoma, B-Cell
  • +2 more
  • Autologous transplantation using rituxan/BEAM
  • Autologous transplantation using Bexxar/BEAM
  • New Haven, Connecticut
  • +35 more
Oct 21, 2021

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023

Brain Gliomas Trial in Suzhou (Allogenic B7H3 CAR-?dT cell)

Recruiting
  • Brain Gliomas
  • Allogenic B7H3 CAR-γδT cell
  • Suzhou, Jiangsu, China
    Dushu Lake Hospital Affiliated to Soochow University
Aug 25, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2023

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)

Recruiting
  • T-lymphoblastic Lymphoma
  • T-ALL
  • CAR-T
  • Shanghai, China
    Shanghai Ruijin Hospital
Nov 14, 2023

AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))

Not yet recruiting
  • AML, Adult
  • Pharmacoscopy
  • Clinical standard-of-care (physician's choice)
  • (no location specified)
Nov 20, 2023

Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

Recruiting
  • Mantle Cell Lymphoma
  • 400mg of TQB3909 tablets
  • 600mg of TQB3909 tablets
  • Beijing, Beijing, China
  • +27 more
Oct 26, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023